Hojong graduated from Seoul National University in South Korea, where he studied total synthesis of bioactive natural product. After graduating, he worked at Korea Institute of Science and Technology to discover kinase inhibitors targeting cancer. As a graduate student in Chemical Biology Program at Harvard, he joined the Graylab in 2017 and is jointly mentored by Dr. Eric Fischer. Hojong is interested in small molecules targeting ubiquitin proteasome system for novel cancer therapeutics.